XML 39 R40.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Long-term Equity-based Compensation Plans - Fair Value Assumptions (Details) (USD $)
In Millions, except Share data, unless otherwise specified
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]    
Options, Outstanding, Weighted Average Remaining Contractual Term 5  
Options, Outstanding, Intrinsic Value $ 6.3  
Options, Vested and Expected to Vest, Outstanding, Number 3,796,343  
Options, Grants in Period, Weighted Average Grant Date Fair Value $ 9.12 $ 7.70
Options, Exercised in Period, Total Intrinsic Value 0.1  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]    
Options, Outstanding at Beginning of the Year 4,004,546  
Options, Outstanding, Weighted Average Exercise Price, Beginning of the Year $ 42.34  
Options, Granted in Period 308,750  
Options, Granted in Period, Weighted Average Exercise Price $ 28.10  
Options, Exercised in Period (12,000)  
Options, Exercised in Period, Weighted Average Exercise Price $ 19.43  
Options, Forfeited and Expired in Period (467,494)  
Options, Forfeited and Expired in Period, Weighted Average Exercise Price $ 46.72  
Options, Outstanding at End of the Period 3,833,802  
Options, Outstanding, Weighted Average Exercise Price, End of the Year $ 40.73  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]    
Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 5  
Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value 6.2  
Options, Vested and Expected to Vest, Exercised, Number 3,082,926  
Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price $ 44.44  
Options, Vested and Expected to Vest, Exercised, Weighted Average Remaining Contractual Term 4  
Options, Vested and Expected to Vest, Exercised, Aggregate Intrinsic Value $ 2.6  
Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 40.87  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 9,950,000  
Restricted Stock [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]    
Restricted Stock, Nonvested Balance at Beginning of the Year 218,156  
Restricted Stock, Nonvested Balance at Beginning of the Year $ 23.72  
Nonvested Restricted Stock, Granted in Period 123,075  
Nonvested Restricted Stock, Granted in Period, Weighted Average Grant Date Fair Value $ 33.25  
Nonvested Restricted Stock, Forfeited in Period (613)  
Nonvested Restricted Stock, Forfeited in Period, Weighted Average Grant Date Fair Value $ 22.07  
Restricted Stock, Nonvested Balance at End of the Period 340,618  
Restrited Stock, Nonvested Balance at End of the Period $ 27.17  
Time Vested Restricted Stock [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]    
Nonvested Restricted Stock, Granted in Period 57,600  
Restricted Stock, Nonvested Balance at End of the Period 164,418  
Performance Based Restricted Stock [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]    
Nonvested Restricted Stock, Granted in Period 65,475  
Restricted Stock, Nonvested Balance at End of the Period 176,200